Zenas BioPharma highlights FDA review acceptance for obexelimab IgG4-RD filing in corporate presentation

• Zenas Biopharma outlined plans to seek US approval for obexelimab in IgG4-related disease, with an FDA decision expected by May 2027.
• Phase 3 INDIGO met its primary endpoint, cutting flare risk 56% versus placebo; 73% of treated patients remained flare-free through week 52.
• Complete remission at week 52 reached 37.1% on obexelimab versus 19.6% on placebo; cumulative rescue glucocorticoid dose fell 65%.
• Pipeline priorities include orelabrutinib Phase 3 programs in progressive multiple sclerosis, with additional Phase 2 readouts for obexelimab in RMS and SLE.
• Royalty Pharma agreement provides up to USD 300 million total investment, including USD 75 million upfront, tied to IgG4-RD and SLE milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.